Key Art Banner

Checklist: A Significant Reduction In Cardiovascular Risk

Amarin’s VASCEPA garners approval for a new and broader use.
Posted on Aug 20, 2020 | 04:55pm
Brought to you by Watch

VASCEPA, a fish-oil derived prescription medication originally approved in 2012 to help lower high triglycerides (a type of fat found in the blood), has recently garnered FDA approval for use in conjunction with a statin (a cholesterol-lowering medication) to reduce overall risk of cardiovascular events. More than 8,000 people with elevated triglyceride levels who were already taking a statin recently took part in a 5-year, randomized study, in which some had VASCEPA added to their regimens. Among the participants who'd been given VASCEPA in addition to their statins, heart attacks or strokes were reduced by a significant 25 percent, and deaths were reduced by 20 percent. 

It's believed that those who would benefit most from VASCEPA are people 45 or older with high triglycerides, who've had a heart attack or stroke, and are already taking a statin; or those over 55 with high triglycerides and diabetes, plus two or more cardiovascular risk factors such as high blood pressure, peripheral vascular disease, or a history of smoking. 

Talk to your doctor to see if VASCEPA is right for you. Read about product information, prescribing information, medication guide, and possible side effects on vascepa.com.

Photo Credit: Anchalee Phanmaha/Getty Images.